摘要
目的研究司库奇尤单抗治疗中重度银屑病患者的疗效和安全性。方法选取2020年5月至2022年12月在首都医科大学宣武医院皮肤科接受司库奇尤单抗治疗的中重度银屑病患者68例,记录患者治疗前后皮损情况、关节损害和甲损伤情况以及银屑病共病情况。结果经司库奇尤单抗治疗后,100%患者达到银屑病面积及严重程度指数(Psoriasis Area and Severity Index,PASI)75改善,87%患者达到PASI 90改善,54.4%患者达到PASI 100改善。司库奇尤单抗可显著改善银屑病性关节炎和甲损害。常见不良反应为上呼吸道感染、注射部位红肿和结膜炎。结论司库奇尤单抗治疗中重度银屑病具有较好的疗效和安全性。
Objective To investigate the efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis.Methods A total of 68 patients with moderate to severe psoriasis who received secukinumab were selected.The skin lesions,joint and nail injuries and psoriasis comorbidities were recorded before and after treatment.Results After treatment with secukinumab,100%of patients achieved PASI 75 improvement,87%of patients achieved PASI 90 improvement,and 54.4%of patients achieved PASI 100 improvement.Secukinumab significantly improved psoriatic arthritis and nail damage.Common adverse reactions were upper respiratory tract infection,injection site redness,and conjunctivitis.Conclusion Secukinumab has good efficacy and safety in the treatment of moderate to severe psoriasis.
作者
陈慧
邹祖鹏
周田田
朱威
Chen Hui;Zou Zupeng;Zhou Tiantian;Zhu Wei(Department of Dermatology,Xuanwu Hospital,Capital Medical University,Beijing 100053,China;Department of Dermatology,Fuxing Hospital,Capital Medical University,Beijing 100038,China)
出处
《中国医学前沿杂志（电子版）》
CSCD
2023年第5期15-18,共4页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
